Ian Cooper’s Stock Pick of the Week

Revisiting the Winners of the Last Few Weeks

Keep an eye on CRISPR Therapeutics (CRSP), we said on November 1.

“The gene editing stock is starting to take off after a favorable US FDA panel review of the drug exa-cel for sickle-cell disease. Now, should the US FDA approve it on the panel’s vote, we could be looking at the first approved drug using the gene-editing technology,” we noted.

At the time, CRSP traded at around $40. Today, it’s up to $71 and could see higher highs, with big catalysts ahead. For one, we’re nearing potential US FDA approval on December 8.

A week later, we highlighted opportunity in Generac Holdings (GNRC), and watched the stock pop from about $109.62 to $122.77.  We still like the stock heading into colder months. Then, we highlighted Editas (EDIT), which should piggyback CRSP, at $10.12. It’s now up to $11.09.

And just last week, we highlighted General Motors (GM) at $28.89 thanks to its buyback and dividend announcements.  That stock is now up to $33 and running.

We’d love to hear how you’re doing with these trade ideas if you have a chance.

Ian Cooper is an experienced trader who uses a combination of technical, fundamental, and news analysis to help individual investors grow their wealth. Ian’s Premium Options Strategies

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.